Global Alpha Antitrypsin Deficiency (AATD) Market Analysis 2020 - Insights, Epidemiology and Market Forecasts to 2030 -

DUBLIN--()--The "Alpha Antitrypsin Deficiency (AATD)- Market Insights, Epidemiology and Market Forecast-2030" drug pipelines has been added to's offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AATDs in the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Alpha Antitrypsin Deficiency (AATD) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

The Alpha Antitrypsin Deficiency (AATD) market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Alpha Antitrypsin Deficiency in the US and Europe.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of AATD, total diagnosed population of AATD, genotype of AATD diagnosed pool and comorbidities associated with AATD) scenario of Alpha Antitrypsin Deficiency (AATD) in the 6MM covering United States and EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2017-2030.

Key Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Key Report Strengths

  • 11 Year Forecast
  • 6MM Coverage

Epidemiology Segmentation

  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Key Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Topics Covered:

1 Key Insights

2 Executive Summary of Alpha Antitrypsin Deficiency

3 SWOT Analysis for Alpha Antitrypsin Deficiency

4 Patient Share of Alpha Antitrypsin Deficiency at a Glance

5 Alpha Antitrypsin Deficiency Market Overview at a Glance

6 Disease Background and Overview

7 Epidemiology and Patient Population

8 Country-wise Epidemiology of Alpha-1-Antitrypsin Deficiency

9 Treatment

10 Treatment Algorithm

11 Unmet Needs

12 Organizations contributing toward Alpha Antitrypsin Deficiency

13 Case Reports

14 Marketed Drugs

15 Emerging Therapies

16 Other Promising Candidates

17 Alpha Antitrypsin Deficiency: 6 Major Market Analysis

18 Alpha Antitrypsin Deficiency: Country-Wise Market Analysis

19 Grifols Initiatives towards Alpha Antitrypsin deficiency

20 US FDA Initiatives for patients with Alpha-1 Antitrypsin Deficiency (AATD)

21 Market Drivers

22 Market Barriers

23 Access and Reimbursement Overview of Alpha Antitrypsin Deficiency

Companies Mentioned

  • Grifols
  • Kamada
  • Shire
  • CSL Behring
  • LFB Biotechnologies
  • Alnylam Pharmaceuticals
  • Arrow Head Pharmaceuticals
  • Vertex Pharmaceuticals
  • Mereo Biopharma
  • Dicerna Pharmaceuticals
  • Inhibrx
  • Vertex Pharmaceuticals

For more information about this drug pipelines report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900